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INTRODUCTION
There has been a decreasing trend in complications of dia-
betes such as diabetic retinopathy or nephropathy due to better
treatment and understanding of the disease. However, the
incidence of lower-extremity amputations resulted from dia-
betic foot ulceration continues to be high (1). Diabetic foot
ulceration is the leading cause of lower-extremity amputa-
tions other than trauma, and the overall risk for amputation
has increased in diabetes 15-fold beyond that for nondiabet-
ic people (2). Foot ulceration results in longer days of hospi-
talization and higher mortality rates in diabetic patients due
to complication with healing failure. It is well accepted that
peripheral neuropathy is a risk factor for developing foot ulcer-
ation, thus early detection and meticulous foot care can reduce
lower extremity amputation rates by about 50-80% (3-7).
Nerve conduction studies have been used as the gold stan-
dard, but can be time-consuming, expensive, and impracti-
cal to operate in a primary care clinic. The Semmes-Weinstein
(SW) monofilament test is simple and inexpensive to use as
a screening tool to identify patients at risk for diabetic foot
complication in primary care setting. Light touch sensation
was measured using SW nylon filaments, which buckle at a
constant known pressure. There are three types of filaments:
4.17, 5.07 and 6.1 (1, 10 and 75-g force, respectively). Birke
et al. (8) examined all three types of the SW monofilaments
in a group of 72 patients with Hansen’s disease and 28 patients
with diabetes mellitus, and concluded that the 5.07/10-g
monofilament was the best indicator of protective sensation. 
The rationale of monofilament test is to measure the patient’s
ability to sense a point of pressure. Inability to sense the 10-g
force pressure is considered as insensate and an independent
predictor for higher risk of foot ulceration (4). Unfortunately,
there is no consensus on how the monofilament is to be used
or the results interpreted, while conceptually simple. Number
of testing sites varied from one to ten, and the criteria for deter-
mining protective sensation, specificity or sensitivity were dif-
ferent in each study (9-14). Thus, we conducted SW monofil-
ament tests on ten sites, and then evaluated the impact of each
site and combinations of sites for testing. 
MATERIALS AND METHODS
We studied 37 type-2 diabetic outpatients at Pusan Nation-
al University Hospital. Their sex, age, duration of diabetes,
fasting serum glucose, HbA1c, and presence of complications
of diabetes were obtained from medical records. Examiner con-
ducted SW monofilament test prior to asking whether patients
noticed any lower-extremity neuropathy symptom (numbness,
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Clinical Usefulness of the Two-site Semmes-Weinstein Monofilament
Test for Detecting Diabetic Peripheral Neuropathy
The present study was done to validate the two-site Semmes-Weinstein (SW)
monofilament test in identifying patients at risk of lower-extremity complications
in clinical setting. The SW monofilament test and nerve conduction study were
conducted on type 2 diabetic patients (n=37) at Pusan National University Hos-
pital in Korea. As the duration of diabetes mellitus was longer, neuropathy iden-
tified by nerve conduction study and complications of diabetes were more severe
(p<0.01). The number of sites unable to perceive SW monofilament (p<0.001) was
larger in patients with lower-extremity neuropathy symptoms than those without
symptoms. Sensitivity and specificity at two sites (the third and fifth metatarsal
head sites) were 93% and 100%, respectively. In conclusion, the two-site SW
monofilament test was a sensitive, specific, simple, and inexpensive screening
tool for identifying diabetic peripheral neuropathy in clinical setting.
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tingling sensation, burning or aching pain) to be blinded from
patient’s perception. Nerve conduction study was followed. 
While patients were unable to observe their feet, the 10 g-
force SW monofilament was used on ten sites of alcohol wiped
foot (Fig. 1). We tested the dorsal surface of the foot between
the base of the first and second toes, the first, third and fifth
toes, the first, third and fifth metatarsal heads, the medial and
lateral midfoot, and the heel in random order. Test sites were
prearranged to examine not only plantar but also various peri-
pheral nerves and dermatomes of the foot.
The SW monofilament was pressed perpendicular to the test
site with enough pressure to bend the monofilament for 1 sec.
Patients were asked to answer “Yes or No”, when felt or did
not feel the press of the monofilament, respectively. If a patient
did not perceive the filament at more than 4 out of 10 sites,
that individual was reported as abnormal and the site(s) was
recorded.
Counterpoint MK II (Dantec, Copenhagen, Denmark) was
used for nerve conduction studies in all patients. Motor con-
duction velocities, distal motor latencies and distal compound
muscle action potential amplitudes of the peroneal and tib-
ial nerves were studied. Additionally, sensory parameters, such
as sensory conduction velocities and amplitudes of the sen-
sory nerve action potentials of the peroneal and sural nerves
were measured according to standard procedures. Room tem-
perature was maintained at 20-25℃to avoid any environmen-
tal variation.
Data were analyzed by SPSS statistical program. Age of pa-
tients with and without symptoms was compared using a two-
sample t-test. Duration of diabetes and HbA1c of patients with
and without symptoms were compared using Wilcoxon’s rank
sum t-test. Sex, the results of SW monofilament test and nerve
conduction study, and complications of diabetes were com-
pared using Fisher’s exact test. Nerve conduction study was
used as gold standard to calculate sensitivity and specificity
of SW monofilament test at each site and then to evaluate the
impact of each site and combinations of sites. Pvalue of <0.05
was required for statistical significance. 
RESULTS
Duration of diabetes was longer among the patients with
lower-extremity neuropathy symptoms than those without
Fig. 1. The sites of Semmes-Weinstein monofilament test.
A B
Number 24  13
Age (yr) (Mean±SD) 57.0± 9.3 62.7±6.8
Sex (%, male)  54.2  53.8
Duration of diabetes mellitus (yr)   14.8± 6.7 8.0±7.1**
(Mean±SD)
HbA1c (%)  9.2± 2.0 9.0±2.0
Semmes-Weinstein monofilament  100.0 (24/24)  53.8 (7/13)
�
(%, abnormal) 
Nerve conduction study   95.8 (23/24)  46.2 (6/13)
�
(%, neuropathy)
Problems complicated  83.3 (20/24)  46.2 (6/13)
�
with diabetes (%) 
Diabetic nephropathy  20.8 (5/24)  7.7 (1/13)
Diabetic retinopathy  0.0 (0/24)  15.4 (2/13)
Diabetic nephropathy and  62.5 (15/24)  23.1 (3/13)
retinopathy
Characteristics With symptom*  Without symptom
Table 1. Characteristics of study subjects
*Symptoms of peripheral neuropathy, **p=0.005 by Wilcoxon’s rank
sum test, 
� p<0.001 by Fisher’s exact test, 
� p<0.01 by Fisher’s exact test. Usefulness of The Two-site SW Monofilament Test 105
symptoms (Table 1). Abnormal SW monofilament results were
observed in 100% of the patients with symptoms, while in
53.8% of patients without symptoms (Table 1). There were
more complications of diabetes among patients with symp-
toms than those without (p<0.01) (Table 1). Patients with sym-
ptoms also had more neuropathy identified by nerve conduc-
tion study than those without symptoms (p<0.01) (Table 1).
Specificity of SW monofilament test was similar (87.5-100
%) at each site, but the sensitivity was varied (20.7-86.2%)
(Table 2). Since 27 out of 29 neuropathy patients identified
as “abnormal” by nerve conduction study had abnormal SW
monofilament test, sensitivity of the test at 10 sites was 93.1%
(Table 3). Diabetic patients without neuropathy symptoms
identified by nerve conduction study also had normal SW
monofilament test, thus specificity of the test at 10 sites was
100% (Table 3). Sensitivity and specificity at two sites (the
No.1  20.7 (6.0-35.4) 100.0 (100.0-100.0)
Abnormal
� 60
Normal 23  8
No.2  34.4 (17.2-51.8) 100.0 (100.0-100.0)
Abnormal 10  0
Normal 19  8
No.3  31.0 (14.2-47.9)  87.5 (64.6-110.4)
Abnormal 9  1 
Normal 20  7 
No.4  44.8 (26.7-62.9)  100.0 (100.0-100.0)
Abnormal 13  0 
Normal 16  8 
No.5  86.2 (73.7-98.8)  100.0 (100.0-100.0)
Abnormal 25  0 
Normal 4  8 
No.6  69.0 (52.1-85.8)  100.0 (100.0-100.0)
Abnormal 20  0 
Normal 9  8 
No.7  65.5 (48.2-82.8)  100.0 (100.0-100.0)
Abnormal 19  0 
Normal 10  8 
No.8  65.5 (44.4-79.7)  100.0 (100.0-100.0)
Abnormal 19  0 
Normal 10  8 
No.9  62.1 (44.4-79.7)  87.5 (64.6-110.4)
Abnormal 18  1 
Normal 11  7 
No.10  0.0 (0.0- 0.9)  100.0 (100.0-100.0)
Abnormal 0 0 
Normal 29  8 
Sensitivity
(95% confidence interval)
Specificity
(95% confidence interval)
Table 2. Sensitivity and specificity of using the 10-g monofilament at each site
Nerve conduction study
Positive (n=29)  Negative  (n=8) 
Sites*
*1. first toe; 2. third toe; 3. fifth toe; 4. first metatarsal head; 5. third metatarsal head; 6. fifth metatarsal head; 7. medial midfoot; 8. lateral midfoot; 9.
Heel; 10. dorsal surface of  foot between the base of the first and second toes. 
� Abnormal if patient was unable to perceive the monofilament at each
site (See Fig. 1).
Abnormal* 27  0 
Normal 2  8 
Table 3. Sensitivity and specificity of using 5.07/10-g monofil-
ament at 10 sites
10 Sites*
*Abnormal if patient was unable to perceive the monofilament at more
than four of 10 sites. Sensitivity (95% confidence interval): 93.1 (83.9-
102.3). Specificity (95% confidence interval): 100.0 (100.0-100.0).
Nerve conduction study
Positive (n=29)  Negative  (n=8) 
Abnormal* 27 0 
Normal 2  8
Table 4. Sensitivity and specificity of the 5.07/10 monofilament
test at two sites
10 Sites*
*Abnormal if patient was unable to perceive monofilament at any of two
(third and fifth metatarsal heads) sites. Sensitivity (95% confidence
interval): 93.1 (83.9-102.3). Specificity (95% confidence interval): 100.0
(100.0-100.0).
Nerve conduction study
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third and fifth metatarsal head sites) were 93.1 and 100%,
same as at 10 sites (Table 4). 
DISCUSSION
The present study was done to validate the SW monofila-
ment test in identifying patients with severe neuropathy to
be at risk of neuropathic ulceration. Nerve conduction test is
used as the gold standard, which is expensive and difficult
to operate in a primary care clinic. Thus, the 5.07/10 g SW
monofilament is recommended by the International Diabetes
Federation and the World Health Organization as a device that
can be used to identify patients at risk of diabetic foot
ulceration, as feasible by health care professionals at every
level. However, there is no guideline on determining test-
ing sites and criteria for determining protective sensation.
Mueller (9), McNeely et al. (4) tested 9 sites, Klenerman et al.
(10) used 6, McGill et al. (11) and Pham et al. (12) studied 5
sites. Holleski et al. (13), Olmos et al. (14), Nagai et al.
(15), and Valk et al.  (16) used 3 sites. Kumar et al. (17)
and Perkins et al. (18) tested only one site, while Duffy et al.
(19), Rith-Najarian et al. (20), and Sosenko et al. (21) suggest-
ed 10 sites. Nagai et al. (15) tested on the first toe, and the
first and the fifth metatarsal heads using 2, 4, and 10 g
monofilaments. They found that the sensitivity and speci-
ficity of the 4 g monofilament in the detection of diabetic
peripheral neuropathy, 85% and 73%, respectively, were
quite close those for the 10 g monofilament (88% and
68%, respectively) (15). In the present study, sensitivity
and specificity were 93.1% and 100%, respectively based
on the definition of insensate as an inability to sense four or
more out of ten sites tested. McGill et al. (11) recommended a
combination of the plantar aspects of the first and fifth
metatarsal because this combination had a sensitivity of
80% and specificity of 86%. They defined “insensate”
when patients did not feel the monofilament at either of
above two sites (11). The sensitivity and specificity were
lower than ours. We found that sensitivity and specificity of
the third and fifth metatarsal heads were higher (93.1%
and 100%, respectively) than other studies. Holleski et al. (13)
reported that specificity was high on the toes and metatarsal
heads, and low on the dorsal surface and the heel. McGill et
al. (11) reported low sensitivity of the first toe and medial
midfoot, while we found that sensitivity of toes and the heel
was low. 
Diabetes ranks the seventh among ten primary chronic dis-
eases in Korea. Every year, 2.2-5.9% of patients with diabetes
mellitus in industrialized nations develop a diabetic foot ulcer.
Diabetic foot ulceration is the key factor that may accelerate
a cascade of events leading to lower-extremity amputation.
Numerous factors can cause diabetic foot ulceration, but peri-
pheral sensory neuropathy is responsible for the most foot
ulcerations. 
As many as 40 to 50% of diabetic patients have neuropa-
thy, which usually occurs in a stocking-glove distribution, with
initial symptoms beginning with paresthesia or dysesthesia
and progressing to complete loss of sensation (24). About 25%
of patients with diabetes for more than 10 yr developed neuro-
pathy and it reached 50% among individuals with more than
20 yr of duration (25). Incidence of diabetic neuropathy is
positively related with age, duration, and hyperglycemia. Neu-
ropathy can be a fatal problem in diabetic patients and eco-
nomic impact of foot ulceration is staggering. Thus, identifi-
cation of patient at risk for foot problem at the early stage is
necessary in preventive intervention. The SW monofilament
test has limitation in quantitative measurement of neuropa-
thy, but is simple, cost-effective, and practical for detecting
peripheral neuropathy. Only one patient with lower-extrem-
ity neuropathy symptoms had normal nerve conduction study
and abnormal SW mono-filament test because monofilament
is not the perfect tool to detect all patients at risk of devel-
oping neuropathic ulcer.
We found that the SW monofilament test was very sensi-
tive and highly specific. Sensitivity and specificity at the third
and fifth metatarsal head sites were comparable to those of
10 sites together. It is likely that the two-site SW monofil-
ament test is useful clinically as a screening device for dia-
betic neuropathy as well as 10-site test. However, since this
was done on small sample of Korean patients with type 2 dia-
betes, larger studies are warranted.
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